Zastosowanie leptyny rekombinowanej w leczeniu różnych typów lipodystrofii Treatment options with recombinant leptin in various types of lipodystrophy.
By:
References
- Rodriguez A.J., Mastronardi C.A., Paz-Filho G.J.: New advances in the treatment of generalized lipodystrophy: Role of metreleptin. Ther. Clin. Risk Manag., 2015; 11: 1391–1400
- Hussain I., Garg A.: Lipodystrophy syndromes. Dermatol. Clin., 2008; 26: 569–578
- Oświęcimska J., Ziora K., Dyduch A.: Lipodystrofia nabyta i wrod-zona. Endokrynol. Otył. Zab. Przem. Mat., 2006; 2: 22–29
- Brown R.J., Araujo-Vilar D., Cheung P.T., Dunger D., Garg A., Jack M., Mungai L., Oral E.A., Patni N., Rother K.I. i wsp.: The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline. J. Clin. Endocrinol. Metab., 2016; 101: 4500–4511
- Bar Akinci B., Sahinoz M., Oral E.: Lipodystrophy syndromes: Presentation and treatment. W: Endotext [Internet], red.: K.R. Fe-ingold, B. Anawalt, A. Boyce, G. Chrousos, W.W. de Herder, K. Dhatariya, K. Dungan, A. Grossman, J.M. Hershman, J. Hofland i wsp., South Dartmoiuth (MA) 2018
- Gonzaga-Jauregui C., Ge W., Staples J., Van Hout C., Yadav A., Colonie R., Leader J.B., Kirchner H.L., Murray M.F., Reid J.G. i wsp.: Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort. Diabetes, 2020; 69: 249–258
- Araújo-Vilar D., Santini F.: Diagnosis and treatment of lipodystrophy: A step-by-step approach. J. Endocrinol. Invest., 2019; 42: 61–73
- Joy T.R., Hegele R.A.: Prevalence of reproductive abnormalities among women with familial partial lipodystrophy. Endocr. Pract., 2008; 14: 1126–1132
- Vantyghem M.C., Vincent-Desplanques D., Defrance-Faivre F., Capeau J., Fermon C., Valat A.S., Lascols O., Hecart A.C., Pigny P., Delemer B. i wsp.: Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy. J. Clin. Endocrinol. Metab., 2008; 93: 2223–2229
- Misra A., Garg A.: Clinical features and metabolic derangements in acquired generalized lipodystrophy Case reports and review of the literature. Medicine, 2003; 82: 129–146
- Gonzalez-Perez R.R., Lanier V., Newman G.: Leptin’s pro-angiogenic signature in breast cancer. Cancers, 2013; 5: 1140–1162
- Karbowska J., Kochan Z.: Leptin as a mediator between obesity and cardiac dysfunction. Postępy Hig. Med. Dośw., 2012; 66: 267–274
- Cammisotto P, Bendayan M.: A review on gastric leptin: The exocrine secretion of a gastric hormone. Anat. Cell Biol., 2012; 45: 1–16
- Denroche H.C., Huynh F.K., Kieffer T.J.: The role of leptin in glucose homeostasis. J. Diabetes Investig., 2012; 3: 115–129
- Brannian J.D., Hansen K.A.: Leptin and ovarian folliculogenesis: Implications for ovulation induction and ART outcomes. Semin. Reprod. Med., 2002; 20: 103–112
- Ramos C.F., Zamoner A.: Thyroid hormone and leptin in the testis. Front. Endocrinol., 2014; 5: 198
- Drugnank. https://go.drugbank.com/drugs/DB09046
- Musso C., Major M.L., Andres E., Simha V.: Metreleptin treatment in three patients with generalized lipodystrophy. Clin. Med. Insights Case Reports, 2017; 9: 123–127
- Vasandani C., Clark G.O., Adams-Huet B., Quittner C., Garg A.: Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: A pilot study. Diabetes Care, 2017; 40: 694–697
- Agencja Oceny Technologii Medycznych i Taryfikacji: Mya-lept (metreleptyna) we wskazaniu: lipodystrofia Dunningana w przebiegu lipodystrofii o dziedziczeniu dominującym związanej z mutacją w genie LMNA. https://bipold.aotm.gov.pl/assets/files/ zlecenia_mz/2018/212/RPT/212_OT.4311.38.2018_Myalept_lipo-dystrofia.pdf
- Rada Przejrzystości działająca przy Prezesie Agencji Oceny Technologii Medycznych i Taryfikacji: Stanowisko Rady Przejrzystości nr 10/2019 z dnia 28 stycznia 2019 roku w sprawie zasadności wydawania zgód na refundację leku Myalept (metreleptyna) we wskazaniu: lipodystrofia Dunningana w przebiegu lipodystrofii o dziedziczeniu dominującym związanej z mutacją w genie LMNA. https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2018/212/ SRP/U_4_34_190128_stanowisko_10_Myalept_metreleptyna_import.pdf
- Park J.Y., Javor E.D., Cochran E.K., DePaoli A.M., Gorden P.: Long-term efficancy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism, 2007; 56: 508–516
- Simha V., Subramanyam L., Szczepaniak L., Quittner C., Adams-Huet B., Snell P., Garg A.: Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypolepti-nemic patients with familial partial lipodystrophy of the Dunnigan variety. J. Clin. Endocrinol. Metab., 2012; 97: 785–792
- Ajluni N., Dar M., Xu J., Neidert A.H., Oral E.A.: Efficacy and safety of metreleptin in patients with partial lipodystrophy: Lessons from an expanded access program. J. Diabetes Metab., 2016; 7: 659
- Vatier C., Fetita S., Boudou P., Tchankou C., Deville L., Riveline J., Young J., Mathivon L., Travert F., Morin D. i wsp.: One-year me-treleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes. Metab., 2016; 18: 693–697
- Araujo-Vilar D., Sánchez-Iglesias S., Guillín-Amarelle C., Castro A., Lage M., Pazos M., Rial J.M., Blasco J., Guillen-Navarro E., Domingo-Jiménez R. i wsp.: Recombinant human leptin treatment in genetic lipodystrophic syndromes: The long-term Spanish experience. Endocrine, 2015; 49: 139–147
- Chan J.L., Lutz K., Cochran E., Huang W., Peters Y., Weyer C., Gorden P.: Clinical effects of long-term metreleptin treatment in patients with lipodystrophy Jean. Endocr. Pract., 2011; 17: 922–932
- Ravussin E., Smith S.R., Mitchell J.A., Shringarpure R., Shan K., Maier H., Koda J.E., Weyer C.: Enhanced weight loss with pram-lintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy. Obesity, 2009; 17: 1736–1743
DOI: https://doi.org/10.2478/ahem-2021-0016 | Journal eISSN: 1732-2693
Language: English
Page range: 815 - 822
Submitted on: Oct 14, 2020
Accepted on: Feb 25, 2021
Published on: Feb 3, 2022
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2022 Hanna Hołysz, Ewa Totoń, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.